Factors Associated with Noncompletion during the Run-In Period before Randomization and Influence on the Estimated Benefit of LCZ696 in the PARADIGM-HF Trial

Medicine & Life Sciences

• LCZ 696 100%
• Random Allocation 60%
• Enalapril 55%
• Heart Failure 25%
• Blood Pressure 16%
• Glomerular Filtration Rate 16%
• Hospitalization 13%
• Neprilysin 11%
• Logistic Models 11%
• Angiotensin Receptors 10%
• Brain Natriuretic Peptide 9%
• Mortality 8%
• Angiotensin-Converting Enzyme Inhibitors 8%
• Cause of Death 6%
• Health Care Outcome Assessment 5%
• Clinical Trials 5%
• Weights and Measures 5%
• Morbidity 5%
• Population 3%
• Therapeutics 1%